We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+7.43%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$994M
AUM Growth
-$12.8M
Cap. Flow
-$17.3M
Cap. Flow %
-1.74%
Top 10 Hldgs %
57.44%
Holding
72
New
15
Increased
6
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$106M
2
COLL icon
Collegium Pharmaceutical
COLL
+$26.7M
3
BPMC
Blueprint Medicines
BPMC
+$25.1M
4
ARDX icon
Ardelyx
ARDX
+$21.7M
5
MDCO
Medicines Co
MDCO
+$19.7M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$49.1M
2
ABUS icon
Arbutus Biopharma
ABUS
+$47.4M
3
DVAX
Dynavax Technologies
DVAX
+$39.9M
4
DYAX
DYAX CORPORATION
DYAX
+$39.9M
5
LRMR icon
Larimar Therapeutics
LRMR
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 75.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$2.08B
$1.1M 0.11%
9,900
-7,700
-44% -$829K
BIIB icon
52
Biogen
BIIB
$30.9B
$1.05M 0.11%
2,600
– –
CELG
53
DELISTED
Celgene Corp
CELG
$1.01M 0.1%
8,700
– –
DRRX
54
DELISTED
DURECT Corp
DRRX
$913K 0.09%
+38,180
New +$897K
ARRY
55
DELISTED
Array Biopharma Inc
ARRY
$909K 0.09%
126,095
-1,231,489
-91% -$9.09M
AMGN icon
56
Amgen
AMGN
$209B
$906K 0.09%
5,900
– –
WGBS
57
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$647K 0.07%
41,080
-10,000
-20% -$205K
KERX
58
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$591K 0.06%
59,200
– –
PBYI icon
59
Puma Biotechnology
PBYI
$398M
$362K 0.04%
3,100
– –
ABUS icon
60
Arbutus Biopharma
ABUS
$847M
– –
-2,714,800
Closed -$47.4M
AKBA icon
61
Akebia Therapeutics
AKBA
$338M
– –
-597,363
Closed -$6.64M
CRDF icon
62
Cardiff Oncology
CRDF
$63M
– –
-8,253
Closed -$4.05M
LRMR icon
63
Larimar Therapeutics
LRMR
$377M
– –
-61,080
Closed -$29M
RGEN icon
64
Repligen
RGEN
$6.91B
– –
-45,000
Closed -$1.37M
RMTI icon
65
Rockwell Medical
RMTI
$27.2M
– –
-2,275
Closed -$2.73M
SCYX icon
66
SCYNEXIS
SCYX
$37.4M
– –
-9,864
Closed -$6.55M
EIGR
67
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-91
Closed -$775K
ARAV
68
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-38,545
Closed -$4.25M
CASC
69
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-194,294
Closed -$1.9M
OCRX
70
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-417,476
Closed -$1.97M
ZSPH
71
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-564,483
Closed -$23.8M
OREX
72
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-118,623
Closed -$9.29M
1 2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, RA Capital Management held 72 positions worth $994M, down 1.3% from $1.01B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

RA Capital Management's Q2 2015 filing shows 15 new, 6 increased, 13 reduced and 13 closed positions. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 625,000 shares worth $102M. The largest sale was BioCryst Pharmaceuticals, an estimated $49.1M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 70% a quarter earlier.

  • RA Capital Management's largest Q2 2015 buy was Sio Gene Therapies Inc. Common Stock: 625,000 shares worth $102M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q2 2015, an estimated $16.4M increase.
  • RA Capital Management's biggest Q2 2015 reduction was BioCryst Pharmaceuticals, cutting an estimated $49.1M.
  • RA Capital Management fully exited Arbutus Biopharma in Q2 2015, selling an estimated $47.4M.
  • RA Capital Management's ten largest holdings make up 57% of its $994M portfolio in Q2 2015.
  • RA Capital Management opened 15 new positions and closed 13 in Q2 2015.
  • RA Capital Management's portfolio value fell 1.3% quarter-over-quarter to $994M.

Based on RA Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.